8EJJ image
Deposition Date 2022-09-16
Release Date 2023-06-07
Last Version Date 2025-06-04
Entry Detail
PDB ID:
8EJJ
Title:
Lassa virus glycoprotein complex (Josiah) bound to S370.7 Fab
Biological Source:
Source Organism:
Host Organism:
Method Details:
Experimental Method:
Resolution:
3.22 Å
Aggregation State:
PARTICLE
Reconstruction Method:
SINGLE PARTICLE
Macromolecular Entities
Structures with similar UniProt ID
Protein Blast
Polymer Type:polypeptide(L)
Molecule:Glycoprotein GP1
Mutagens:H207C
Chain IDs:A, B, C
Chain Length:197
Number of Molecules:3
Biological Source:Lassa mammarenavirus
Polymer Type:polypeptide(L)
Molecule:S370.7 heavy chain Fab
Chain IDs:D (auth: H), E (auth: I), K (auth: h)
Chain Length:128
Number of Molecules:3
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Molecule:S370.7 light chain Fab
Chain IDs:F (auth: J), G (auth: L), L (auth: l)
Chain Length:107
Number of Molecules:3
Biological Source:Homo sapiens
Structures with similar UniProt ID
Protein Blast
Polymer Type:polypeptide(L)
Molecule:Glycoprotein GP2
Mutagens:L257R, L258R, E328P, G359C
Chain IDs:H (auth: a), I (auth: b), J (auth: c)
Chain Length:197
Number of Molecules:3
Biological Source:Lassa mammarenavirus
Primary Citation
Structural conservation of Lassa virus glycoproteins and recognition by neutralizing antibodies.
Cell Rep 42 112524 112524 (2023)
PMID: 37209096 DOI: 10.1016/j.celrep.2023.112524

Abstact

Lassa fever is an acute hemorrhagic fever caused by the zoonotic Lassa virus (LASV). The LASV glycoprotein complex (GPC) mediates viral entry and is the sole target for neutralizing antibodies. Immunogen design is complicated by the metastable nature of recombinant GPCs and the antigenic differences among phylogenetically distinct LASV lineages. Despite the sequence diversity of the GPC, structures of most lineages are lacking. We present the development and characterization of prefusion-stabilized, trimeric GPCs of LASV lineages II, V, and VII, revealing structural conservation despite sequence diversity. High-resolution structures and biophysical characterization of the GPC in complex with GP1-A-specific antibodies suggest their neutralization mechanisms. Finally, we present the isolation and characterization of a trimer-preferring neutralizing antibody belonging to the GPC-B competition group with an epitope that spans adjacent protomers and includes the fusion peptide. Our work provides molecular detail information on LASV antigenic diversity and will guide efforts to design pan-LASV vaccines.

Legend

Protein

Chemical

Disease

Primary Citation of related structures